Picard Issues Statement on Intraday Stock Price
Picard Medical (NYSE American: PMI) on October 24, 2025 said it is not aware of any undisclosed material change in its operations or financial condition that would explain recent intraday stock volatility. The company stated it remains focused on executing strategic and operational priorities and will continue to meet disclosure obligations under applicable securities laws.
Investors are directed to the company website and SEC filings for additional information.
Picard Medical (NYSE American: PMI) il 24 ottobre 2025 ha dichiarato di non essere a conoscenza di alcun cambiamento materiale non divulgato nelle sue operazioni o nel suo stato finanziario che spiegherebbe la recente volatilità intraday delle azioni. L'azienda ha dichiarato di rimanere focalizzata sull'esecuzione delle priorità strategiche e operative e continuerà a soddisfare gli obblighi di divulgazione previsti dalle leggi sui titoli applicabili.
Si invita gli investitori a consultare il sito web dell'azienda e i documenti SEC per ulteriori informazioni.
Picard Medical (NYSE American: PMI) en el 24 de octubre de 2025 señaló que no tiene conocimiento de ningún cambio material no divulgado en sus operaciones o situación financiera que explique la reciente volatilidad intradía de las acciones. La compañía declaró que continúa enfocada en ejecutar las prioridades estratégicas y operativas y seguirá cumpliendo con las obligaciones de divulgación conforme a las leyes de valores aplicables.
Los inversionistas deben consultar en el sitio web de la empresa y en los archivados de la SEC para obtener información adicional.
Picard Medical (NYSE American: PMI)는 2025년 10월 24일에 비공개의 주요 변경 사항으로 주식의 최근 장중 변동을 설명할 수 있는 내용이 없다고 밝혔습니다. 회사는 전략적 및 운영상의 우선순위를 실행하는 데 계속 집중하고 있으며 적용 가능한 증권법에 따른 공시 의무를 계속 이행할 것이라고 밝혔습니다.
추가 정보는 회사 웹사이트 및 SEC 제출 문서를 참조하시기 바랍니다.
Picard Medical (NYSE American: PMI) le 24 octobre 2025 a déclaré qu'il n'a connaissance d'aucun changement important non divulgué dans ses opérations ou sa situation financière qui expliquerait la récente volatilité intrajournalière des actions. L'entreprise a déclaré qu'elle reste concentrée sur l'exécution des priorités stratégiques et opérationnelles et continuera de répondre aux obligations de divulgation en vertu des lois sur les valeurs mobilières applicables.
Les investisseurs sont dirigés vers le site web de l'entreprise et les dépôts auprès de la SEC pour des informations supplémentaires.
Picard Medical (NYSE American: PMI) am 24. Oktober 2025 erklärte, dass ihr keine nicht offengelegten wesentlichen Veränderungen in ihren Betrieben oder ihrer finanziellen Lage bekannt seien, die die jüngste intraday-Volatilität der Aktien erklären würden. Das Unternehmen erklärte, dass es weiterhin auf die Umsetzung strategischer und operativer Prioritäten fokussiert bleibt und seine Offenlegungspflichten nach geltendem Wertpapierrecht erfüllen wird.
Investoren werden auf die Website des Unternehmens und SEC-Unterlagen für weitere Informationen verwiesen.
Picard Medical (NYSE American: PMI) في 24 أكتوبر 2025 قال إنه لا يعلم بأي تغيير مادي غير مُعلن في عملياته أو حالته المالية يفسر تقلب سعر السهم خلال الجلسة الأخيرة. صرّحت الشركة بأنها ما زالت مركّزة على تنفيذ الأولويات الاستراتيجية والتشغيلية وأنها ستستمر في الالتزام بمتطلبات الإبلاغ وفقاً لقوانين الأوراق المالية المعمول بها.
يُوجّه المستثمرون إلى موقع الشركة على الويب وملفات هيئة الأوراق المالية والبدء في الحصول على معلومات إضافية.
Picard Medical (NYSE American: PMI) 于 2025年10月24日 宣布，未发现任何未披露的重大经营或财务状况变化可解释近期盘中股价波动。公司表示仍专注于执行战略与运营优先事项，并将继续遵守适用证券法下的披露义务。
投资者可浏览公司网站及美国证券交易委员会的文件以获取更多信息。
- None.
- None.
TUCSON, Ariz., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced that it is not aware of any undisclosed material change in the Company’s operations or financial condition, that would account for the recent volatility in its stock price.
The Company remains focused on executing its strategic and operational priorities and will continue to comply with all disclosure obligations under applicable securities laws.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com
Forward-Looking Statements
This release may contain forward-looking statements within the meaning of federal securities laws. Such statements are based on current expectations and are subject to risks and uncertainties that may cause actual results to differ materially. The Company undertakes no obligation to update or revise any forward-looking statements.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ
What did Picard Medical (PMI) announce on October 24, 2025 about its stock price?
Does the October 24, 2025 Picard statement (PMI) include new financial results or guidance?
Where can investors find more information after Picard's October 24, 2025 statement (PMI)?
Will Picard (PMI) change its disclosure practices after the October 24, 2025 notice?
Should PMI shareholders expect operational changes after the October 24, 2025 statement?
